Cambridge, Massachusetts-based Neon Therapeutics, an immuno-oncology company developing neoantigen-based therapeutic vaccines and T cell therapies to treat cancer, has debuted its IPO after pricing its 6.25 million shares at $16 per share. The stock began trading June 27, 2018 on the NASDAQ under the ticker symbol “NTGN.” Morgan Stanley, BofA Merrill Lynch and Mizuho Securities are the lead underwriters. Neon Therapeutics’ pre-IPO backers include Partner Fund Management, Third Rock Ventures, Access Industries, Fidelity Management & Research Company, Wellington Management Company, Inbio Ventures and Nextech Invest.
CAMBRIDGE, Mass., June 26, 2018 (GLOBE NEWSWIRE) — Neon Therapeutics, Inc. (Nasdaq:NTGN), a clinical-stage immuno-oncology company developing neoantigen-based therapeutics, today announced the pricing of its initial public offering of 6,250,000 shares of common stock at a public offering price of $16.00 per share, before underwriting discounts and commissions. In addition, Neon Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 937,500 shares of common stock at the initial public offering price, less the underwriting discounts and commissions. Neon’s common stock is expected to begin trading on The Nasdaq Global Select Market on June 27, 2018 under the ticker symbol “NTGN.” All of the common stock is being offered by Neon Therapeutics. The gross proceeds of the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Neon, are expected to be $100.0 million, excluding any exercise of the underwriters’ option to purchase additional shares. The offering is expected to close on June 29, 2018, subject to the satisfaction of customary closing conditions.
Morgan Stanley, BofA Merrill Lynch and Mizuho Securities are acting as joint book-running managers for the offering. Oppenheimer & Co. is acting as lead manager for the offering.
A registration statement relating to the shares being sold in this offering was declared effective by the Securities and Exchange Commission on June 26, 2018. The offering is being made only by means of a prospectus. Copies of the final prospectus may be obtained, when available, from Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014; BofA Merrill Lynch, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attention: Prospectus Department, or by email at firstname.lastname@example.org; or Mizuho Securities USA LLC, Attention: Equity Capital Markets, 320 Park Ave., New York, New York 10022, or by e-mail at US-ECM@us.mizuho-sc.com, or by telephone at (212) 205-7600.
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Neon Therapeutics
Neon Therapeutics is a clinical-stage immuno-oncology company and a leader in the field of neoantigen-targeted therapies, dedicated to transforming the treatment of cancer by directing the immune system towards neoantigens.